Trial · NCT02097225
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 152
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thromboembolic Event | Vascular disorders | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 1 | 3 | |
| other | Thromboembolic Event | Vascular disorders | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | 1 | 4 | |
| other | Thromboembolic Event | Vascular disorders | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | 0 | 6 | |
| other | Thromboembolic Event | Vascular disorders | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | 0 | 8 | |
| other | Abdominal Pain | Gastrointestinal disorders | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 0 | 3 | |
| other | Abdominal Pain | Gastrointestinal disorders | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | 2 | 4 | |
| other | Abdominal Pain | Gastrointestinal disorders | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | 0 | 6 | |
| other | Abdominal Pain | Gastrointestinal disorders | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | 0 | 8 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 0 | 3 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | 1 | 4 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | 0 | 6 | |
| other | Constipation | Gastrointestinal disorders | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | 0 | 8 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 0 | 3 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | 1 | 4 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | 0 | 6 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | 0 | 8 | |
| other | Fatigue | General disorders | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 0 | 3 | |
| other | Fatigue | General disorders | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | 0 | 4 | |
| other | Fatigue | General disorders | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | 2 | 6 | |
| other | Fatigue | General disorders | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | 1 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02097225/events